论文部分内容阅读
目的观察DC-CIK细胞对荷B细胞淋巴瘤SCID小鼠的抑瘤作用及安全性。方法分别培养DC、CIK细胞和Namalwa细胞,用流式检测DC-CIK细胞的免疫表型,用MTT法检测DC-CIK细胞的溶瘤效应。采用4~5周龄的CB-17 SCID小鼠26只,每只经腹腔接种7.5×106Namalwa细胞制备人B细胞淋巴瘤模型。将荷瘤9 d的SCID小鼠随机分为盐水组、环磷酰胺组、DC-CIK细胞治疗组。观察荷瘤SCID小鼠的存活时间及不良反应。结果 DC与CIK细胞共培养6 d时,CD3+CD56+双阳性细胞为28.4%。在1∶5、1∶10和1∶20效靶比时,DC-CIK细胞对Namalwa细胞的杀伤率分别是75.34%±9.34%,82.30%±9.18%和90.73%±3.81%。SCID小鼠的中位成瘤时间为(18.67±1.94)d。盐水组、环磷酰胺组和细胞组的中位生存时间分别为(28.00±6.36)d、(35.17±9.77)d和(47.67±6.30)d,与盐水组比较,细胞治疗组的生存时间延长(19.67±4.73)d,差异有统计学意义(P<0.05);而环磷酰胺组和细胞治疗组比较差异无统计学意义。在实验中未观察到荷瘤鼠有明显的不良反应。结论 DC-CIK细胞能延长荷B细胞淋巴瘤SCID小鼠的生存期,且无明显的不良反应。
Objective To observe the anti-tumor effect and safety of DC-CIK cells on SCID mice bearing B-cell lymphoma. Methods DC, CIK cells and Namalwa cells were cultured. The immunophenotypes of DC-CIK cells were detected by flow cytometry. The oncolytic effect of DC-CIK cells was detected by MTT assay. Twenty-six CB-17 SCID mice aged 4-5 weeks were used to prepare human B cell lymphoma model by intraperitoneally inoculation of 7.5 × 106Namalwa cells. The SCID mice bearing tumor for 9 d were randomly divided into saline group, cyclophosphamide group and DC-CIK cell treatment group. The survival time and adverse reactions of tumor-bearing SCID mice were observed. Results When DC and CIK cells were co-cultured for 6 days, CD3 + CD56 + double positive cells were 28.4%. The cytotoxicity of DC-CIK cells to Namalwa cells was 75.34% ± 9.34%, 82.30% ± 9.18% and 90.73% ± 3.81% at 1:5, 1:10 and 1:20 effective targets respectively. The median tumor formation time of SCID mice was (18.67 ± 1.94) d. The median survival time of saline group, cyclophosphamide group and cell group were (28.00 ± 6.36) days, (35.17 ± 9.77) days and (47.67 ± 6.30) days, respectively. Compared with saline group, the survival time of cell treatment group was prolonged (19.67 ± 4.73) d, the difference was statistically significant (P <0.05); while there was no significant difference between cyclophosphamide group and cell therapy group. Tumor-bearing mice were not observed in the experiment had obvious adverse reactions. Conclusion DC-CIK cells can prolong the survival of SCID mice bearing B-cell lymphoma without obvious adverse reactions.